Interactions between antiepileptics and second-generation antipsychotics

被引:68
|
作者
de Leon, Jose [1 ,3 ]
Santoro, Vincenza [2 ]
D'Arrigo, Concetta [2 ]
Spina, Edoardo [2 ]
机构
[1] Univ Kentucky, Mental Hlth Res Ctr, Eastern State Hosp, Lexington, KY 40508 USA
[2] Univ Messina, Dept Clin & Expt Med & Pharmacol, Pharmacol Sect, Messina, Italy
[3] Univ Granada, Inst Neurosci Psychiat & Neurosci Res Grp CTS 549, Granada, Spain
关键词
amisulpride; anticonvulsants; antipsychotics; aripiprazole; asenapine; bipolar disorder; carbamazepine; clozapine; drug interactions; eslicarbazepine; ethosuximide; felbamate; gabapentin; iloperidone; lacosamide; lamotrigine; levetiracetam; lurasidone; olanzapine; oxcarbazepine; paliperidone; pharmacokinetics; phenobarbital; phenytoin; pregabalin; primidone; quetiapine; retigabine; risperidone; rufinamide; stiripentol; tiagabine; topiramate; valproate; vigabatrin; ziprasidone; zonisamide; STEADY-STATE PHARMACOKINETICS; DRUG-MONITORING SERVICE; PLASMA CLOZAPINE CONCENTRATIONS; RANDOMIZED CONTROLLED-TRIAL; OLANZAPINE SERUM CONCENTRATIONS; MAJOR DEPRESSIVE DISORDER; PREGNANE-X RECEPTOR; BIPOLAR I DISORDER; OF-THE-LITERATURE; VALPROIC ACID;
D O I
10.1517/17425255.2012.660918
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Introduction: Pharmacokinetic and pharmacodynamic drug interactions (DIs) can occur between antiepileptics (AEDs) and second-generation antipsychotics (SGAPs). Some AED and SGAP pharmacodynamic mechanisms are poorly understood. AED--SGAP combinations are used for treating comorbid illnesses or increasing efficacy, particularly in bipolar disorder. Areas covered: This article provides a comprehensive review of the interactions between antiepileptics and second-generation antipsychotics. The authors cover pharmacokinetic AED--SGAP DI studies, the newest drug pharmacokinetics in addition to the limited pharmacodynamic DI studies. Expert opinion: Dosing correction factors and measuring SGAP levels can help to compensate for the inductive properties of carbamazepine, phenytoin, phenobarbital and primidone. Further studies are needed to establish the clinical relevance of combining: i) AED strong inducers with amisulpride, asenapine, iloperidone, lurasidone and paliperidone; ii) valproate with aripiprazole, asenapine, clozapine and olanzapine; iii) high doses of oxcarbazepine (1500 mg/day) or topiramate (>= 400 mg/day) with aripiprazole, lurasidone, quetiapine, risperidone, asenapine and olanzapine. Two pharmacodynamic DIs are beneficial: i) valproate-SGAP combinations may have additive effects in bipolar disorder, ii) combining topiramate or zonisamide with SGAPs may decrease weight gain. Three pharmacodynamic DIs contributing to decreased safety are common: sedation, weight gain and swallowing disturbances. A few AED--SGAP combinations may increase risk for osteoporosis or nausea. Three potentially lethal but rare pharmacodynamic DIs include pancreatitis, agranulocytosis/leukopenia and heat stroke. The authors believe that collaboration is needed from drug agencies and pharmaceutical companies, the clinicians using these combinations, researchers with expertise in meta-analyses, grant agencies, pharmacoepidemiologists and DI pharmacologists for future progression in this field.
引用
收藏
页码:311 / 334
页数:24
相关论文
共 50 条
  • [1] Clinically relevant interactions between newer antidepressants and second-generation antipsychotics
    Spina, Edoardo
    de Leon, Jose
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2014, 10 (05) : 721 - 746
  • [2] Interactions between the cytochrome P450 system and the second-generation antipsychotics
    Prior, TI
    Baker, GB
    JOURNAL OF PSYCHIATRY & NEUROSCIENCE, 2003, 28 (02): : 99 - 112
  • [3] Pharmacogenetics of second-generation antipsychotics
    Brennan, Mark D.
    PHARMACOGENOMICS, 2014, 15 (06) : 869 - 884
  • [4] Switching between second-generation antipsychotics -: Why and how?
    Edlinger, M
    Baumgartner, S
    Eltanaihi-Furtmüller, N
    Hummer, M
    Fleischhacker, WW
    CNS DRUGS, 2005, 19 (01) : 27 - 42
  • [5] Relationship between P-glycoprotein and second-generation antipsychotics
    Moons, Tim
    de Roo, Mariska
    Claes, Stephan
    Dom, Geert
    PHARMACOGENOMICS, 2011, 12 (08) : 1193 - 1211
  • [6] Second-generation antipsychotics and the metabolic syndrome
    Prakash S. Masand
    Rajnish Mago
    Current Psychiatry Reports, 2005, 7 (3) : 153 - 154
  • [7] First- and Second-Generation Antipsychotics
    McEvoy, Joseph P.
    Zigman, Daniel
    Margolese, Howard C.
    CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2010, 55 (03): : 144 - 149
  • [8] Second-generation antipsychotics for anxiety disorders
    Depping, Anna M.
    Komossa, Katja
    Kissling, Werner
    Leucht, Stefan
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2010, (12):
  • [9] Second-Generation Antipsychotics and VTE Risk
    Deloughery, Emma P.
    BLOOD, 2023, 142
  • [10] Second-generation antipsychotics: a therapeutic downturn?
    Lewis, Shon
    PSYCHOLOGICAL MEDICINE, 2009, 39 (10) : 1603 - 1606